These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

427 related items for PubMed ID: 11555613

  • 1. Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype.
    Hobisch A, Ramoner R, Fuchs D, Godoy-Tundidor S, Bartsch G, Klocker H, Culig Z.
    Clin Cancer Res; 2001 Sep; 7(9):2941-8. PubMed ID: 11555613
    [Abstract] [Full Text] [Related]

  • 2. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
    Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A, Bartsch G, Utermann G, Schneider MR, Parczyk K, Klocker H.
    Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
    [Abstract] [Full Text] [Related]

  • 3. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression.
    Lee SO, Chun JY, Nadiminty N, Lou W, Gao AC.
    Prostate; 2007 May 15; 67(7):764-73. PubMed ID: 17373716
    [Abstract] [Full Text] [Related]

  • 4. Prostate cancer cells generated during intermittent androgen ablation acquire a growth advantage and exhibit changes in epidermal growth factor receptor expression.
    Hobisch A, Fiechtl M, Sandahl-Sorensen B, Godoy-Tundidor S, Artner-Dworzak E, Ramoner R, Bartsch G, Culig Z.
    Prostate; 2004 Jun 01; 59(4):401-8. PubMed ID: 15065088
    [Abstract] [Full Text] [Related]

  • 5. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor.
    Hobisch A, Eder IE, Putz T, Horninger W, Bartsch G, Klocker H, Culig Z.
    Cancer Res; 1998 Oct 15; 58(20):4640-5. PubMed ID: 9788616
    [Abstract] [Full Text] [Related]

  • 6. Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1.
    Zaia A, Fraizer GC, Piantanelli L, Saunders GF.
    Anticancer Res; 2001 Oct 15; 21(1A):1-10. PubMed ID: 11299720
    [Abstract] [Full Text] [Related]

  • 7. The androgen receptor pathway is by-passed in prostate cancer cells generated after prolonged treatment with bicalutamide.
    Hobisch A, Fritzer A, Comuzzi B, Fiechtl M, Malinowska K, Steiner H, Bartsch G, Culig Z.
    Prostate; 2006 Mar 01; 66(4):413-20. PubMed ID: 16302272
    [Abstract] [Full Text] [Related]

  • 8. Curcumin blocks the activation of androgen and interlukin-6 on prostate-specific antigen expression in human prostatic carcinoma cells.
    Tsui KH, Feng TH, Lin CM, Chang PL, Juang HH.
    J Androl; 2008 Mar 01; 29(6):661-8. PubMed ID: 18676361
    [Abstract] [Full Text] [Related]

  • 9. Variants of the human prostate LNCaP cell line as tools to study discrete components of the androgen-mediated proliferative response.
    Soto AM, Lin TM, Sakabe K, Olea N, Damassa DA, Sonnenschein C.
    Oncol Res; 1995 Mar 01; 7(10-11):545-58. PubMed ID: 8866667
    [Abstract] [Full Text] [Related]

  • 10. Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer.
    Zerbini LF, Wang Y, Cho JY, Libermann TA.
    Cancer Res; 2003 May 01; 63(9):2206-15. PubMed ID: 12727841
    [Abstract] [Full Text] [Related]

  • 11. Androgens stimulate fatty acid synthase in the human prostate cancer cell line LNCaP.
    Swinnen JV, Esquenet M, Goossens K, Heyns W, Verhoeven G.
    Cancer Res; 1997 Mar 15; 57(6):1086-90. PubMed ID: 9067276
    [Abstract] [Full Text] [Related]

  • 12. An autocrine loop for vascular endothelial growth factor is established in prostate cancer cells generated after prolonged treatment with interleukin 6.
    Steiner H, Berger AP, Godoy-Tundidor S, Bjartell A, Lilja H, Bartsch G, Hobisch A, Culig Z.
    Eur J Cancer; 2004 May 15; 40(7):1066-72. PubMed ID: 15093584
    [Abstract] [Full Text] [Related]

  • 13. Butyrate analogue, isobutyramide, inhibits tumor growth and time to androgen-independent progression in the human prostate LNCaP tumor model.
    Gleave ME, Sato N, Sadar M, Yago V, Bruchovsky N, Sullivan L.
    J Cell Biochem; 1998 Jun 01; 69(3):271-81. PubMed ID: 9581866
    [Abstract] [Full Text] [Related]

  • 14. E2F activity is biphasically regulated by androgens in LNCaP cells.
    Hofman K, Swinnen JV, Verhoeven G, Heyns W.
    Biochem Biophys Res Commun; 2001 Apr 27; 283(1):97-101. PubMed ID: 11322773
    [Abstract] [Full Text] [Related]

  • 15. Interleukin-4 stimulates androgen-independent growth in LNCaP human prostate cancer cells.
    Lee SO, Pinder E, Chun JY, Lou W, Sun M, Gao AC.
    Prostate; 2008 Jan 01; 68(1):85-91. PubMed ID: 18008330
    [Abstract] [Full Text] [Related]

  • 16. Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway.
    Steiner H, Godoy-Tundidor S, Rogatsch H, Berger AP, Fuchs D, Comuzzi B, Bartsch G, Hobisch A, Culig Z.
    Am J Pathol; 2003 Feb 01; 162(2):655-63. PubMed ID: 12547723
    [Abstract] [Full Text] [Related]

  • 17. Interleukin-4 in patients with prostate cancer.
    Takeshi U, Sadar MD, Suzuki H, Akakura K, Sakamoto S, Shimbo M, Suyama T, Imamoto T, Komiya A, Yukio N, Ichikawa T.
    Anticancer Res; 2005 Feb 01; 25(6C):4595-8. PubMed ID: 16334148
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of LncaP prostate cancer cells by means of androgen receptor antisense oligonucleotides.
    Eder IE, Culig Z, Ramoner R, Thurnher M, Putz T, Nessler-Menardi C, Tiefenthaler M, Bartsch G, Klocker H.
    Cancer Gene Ther; 2000 Jul 01; 7(7):997-1007. PubMed ID: 10917202
    [Abstract] [Full Text] [Related]

  • 19. Beta-2-microglobulin is an androgen-regulated secreted protein elevated in serum of patients with advanced prostate cancer.
    Gross M, Top I, Laux I, Katz J, Curran J, Tindell C, Agus D.
    Clin Cancer Res; 2007 Apr 01; 13(7):1979-86. PubMed ID: 17404077
    [Abstract] [Full Text] [Related]

  • 20. Regulation of prostate-specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide.
    Rekasi Z, Schally AV, Plonowski A, Czompoly T, Csernus B, Varga JL.
    Prostate; 2001 Aug 01; 48(3):188-99. PubMed ID: 11494334
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.